<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606264</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19030022</org_study_id>
    <nct_id>NCT04606264</nct_id>
  </id_info>
  <brief_title>Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data</brief_title>
  <official_title>UPMC REMAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Surgical Pathways Enhancing Recovery (SUPER) - Enhanced Recovery Protocols (ERP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Holder-Murray</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berry Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This REMAP SUPER ERP domain study falls under the SUPER Core Protocol, which compares the&#xD;
      different recommended strategies for enhancing recovery through the use of various standard&#xD;
      of care treatments before, during and after surgery in all patients with elective surgical&#xD;
      encounters at UPMC who meet eligibility criteria.&#xD;
&#xD;
      The ERP domain seeks to enhance recovery by optimizing strategies of perioperative care&#xD;
      through evaluating combinations of perioperative treatment, which consists of preoperative,&#xD;
      intraoperative and postoperative care. Optimal combinations of perioperative care will be&#xD;
      generated and analyzed to determine the best outcomes for patients as defined by reduction in&#xD;
      hospital free days, reduction in postoperative nausea and vomiting, and improved pain&#xD;
      control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SUPER Core Protocol is an administration structure designed to provide appropriate&#xD;
      management of all aspects of the study, taking into account multiple factors including&#xD;
      representation from clinics and hospitals that are participating in the trial, availability&#xD;
      of skills and expertise related to trial conduct and statistical analysis, and content&#xD;
      knowledge regarding acute illness, elective surgery, and the interventions that are being&#xD;
      evaluated. Eligible patients will be randomized to a recommended set of standard of care&#xD;
      treatments related to their surgery to identify those that improve outcomes as defined by&#xD;
      hospital free days at 30 days from the date of the surgical encounter. The administration&#xD;
      model is designed to provide effective operational and strategic management of the REMAP that&#xD;
      operates in multiple UPMC facilities, is supported by multiple funding bodies and sponsors,&#xD;
      and will evolve with addition of domains and interventions that are being evaluated.&#xD;
&#xD;
      The ERP domain under the SUPER Core Protocol will evaluate the varying recommended&#xD;
      combinations of perioperative treatments, in hopes to determine the optimal strategies for&#xD;
      perioperative care based on surgery type and patient specific factors. In this study, patient&#xD;
      care components within the preoperative, perioperative, and postoperative domains will be&#xD;
      randomized with a machine learning REMAP technique. Optimal strategies combining the entire&#xD;
      perioperative process will be analyzed that determine best outcomes for patients including&#xD;
      hospital free days, reductions in postoperative nausea and vomiting, and improved pain&#xD;
      control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 day hospital free days</measure>
    <time_frame>Day 0 - Day 30</time_frame>
    <description>The primary endpoint for this domain is the REMAP SUPER primary outcome of hospital free days at 30 days after the elective surgical encounter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in postoperative nausea and vomiting (PONV) by measurement of antiemetics medication use within 24 hours post surgery</measure>
    <time_frame>0 - 24 hours post surgery</time_frame>
    <description>Change in number of doses of antiemetics administered 24 hours post surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postoperative nausea and vomiting (PONV) by measurement incidences of emesis within 24 hours post surgery</measure>
    <time_frame>0 - 24h post surgery</time_frame>
    <description>Change in number of incidences of emesis 24h post surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the rate of postoperative opioid use by measurement of oral morphine equivalents (OME) postoperative day 0 to postoperative day 5</measure>
    <time_frame>Day 0 - Day 5</time_frame>
    <description>Change in the rate (mg/day) of Oral Morphine Equivalents administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in opioid consumption following postoperative discharge at 6 months</measure>
    <time_frame>0-6 months</time_frame>
    <description>Change in opioid prescription/administration following discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of complications up to 30 days after surgical procedure</measure>
    <time_frame>Day 0 - Day 30</time_frame>
    <description>Readmission or complications due to surgery on or before 30 days of surgical procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of adverse events up to 30 days after surgical procedure</measure>
    <time_frame>Day 0 - Day 30</time_frame>
    <description>Incidences of adverse events as define in core protocol</description>
  </secondary_outcome>
  <number_of_arms>38</number_of_arms>
  <enrollment type="Anticipated">35485</enrollment>
  <condition>Perioperative Optimization</condition>
  <arm_group>
    <arm_group_label>Major Abdominal: Preoperative Oral Hydration Gatorade:</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Preoperative Oral Hydration CarbRich Beverage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Preoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: No Preoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Neuraxial Analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Regional Analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: PONV Prophylaxis Perphenazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: PONV Prophylaxis Aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Primary Anesthetic Volatile Agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Primary Anesthetic TIVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Fluid Therapy Stroke Volume Optimization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Fluid Therapy Maintain Euvolemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Analgesia Adjuncts Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Anesthesia Adjuncts Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Anesthesia Adjuncts Ketamine and Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: No Anesthesia Adjuncts</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Intraoperative Opioid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: No Intraoperative Opioid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: Postoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Major Abdominal: No Postoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Preoperative Oral Hydration Gatorade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Oral Hydration CarbRich Beverage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Preoperative Oral Analgesia Adjunct Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: No Preoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Neuraxial Analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Regional Analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: PONV Prophylaxis Perphenazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: PONV Prophylaxis Aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Primary Anesthetic Volatile Agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Primary Anesthetic Spinal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Fluid Therapy Stroke Volume Optimization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Fluid Therapy Maintain Euvolemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Analgesia Adjuncts Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Intraoperative Opioid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: No Intraoperative Opioid</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Postoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: No Postoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic: Primary Anesthetic TIVA (Propofol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gatorade ®</intervention_name>
    <description>This randomized group will be asked to drink a specific amount of Gatorade ® the night before and 2-3 hours prior to their procedure.</description>
    <arm_group_label>Major Abdominal: Preoperative Oral Hydration Gatorade:</arm_group_label>
    <arm_group_label>Orthopedic: Preoperative Oral Hydration Gatorade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Clearfast ®</intervention_name>
    <description>The randomized group will be asked to drink a specific amount of Clearfast ® the night before and 2-3 hours prior to their procedure.</description>
    <arm_group_label>Major Abdominal: Preoperative Oral Hydration CarbRich Beverage</arm_group_label>
    <arm_group_label>Orthopedic: Oral Hydration CarbRich Beverage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preoperative Gabapentin</intervention_name>
    <description>This randomized group will receive gabapentin depending on age of each patient. If patients age &lt;65, receive 1 dose of 600mg gabapentin. If patients age ≥ 65 receive 1 dose of 300mg.</description>
    <arm_group_label>Major Abdominal: Preoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_label>Orthopedic: Preoperative Oral Analgesia Adjunct Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neuraxial Morphine Injection</intervention_name>
    <description>This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).</description>
    <arm_group_label>Major Abdominal: Neuraxial Analgesia</arm_group_label>
    <arm_group_label>Orthopedic: Neuraxial Analgesia</arm_group_label>
    <other_name>Intrathecal morphine/hydromorphone</other_name>
    <other_name>IT morphine/hydromorphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regional Technique Analgesia</intervention_name>
    <description>This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)</description>
    <arm_group_label>Major Abdominal: Regional Analgesia</arm_group_label>
    <arm_group_label>Orthopedic: Regional Analgesia</arm_group_label>
    <other_name>Nerve Block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perphenazine</intervention_name>
    <description>This randomized group will receive 8 mg of perphenazine orally preoperatively.</description>
    <arm_group_label>Major Abdominal: PONV Prophylaxis Perphenazine</arm_group_label>
    <arm_group_label>Orthopedic: PONV Prophylaxis Perphenazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>This randomized group will receive 80 mg of aprepitant orally preoperatively.</description>
    <arm_group_label>Major Abdominal: PONV Prophylaxis Aprepitant</arm_group_label>
    <arm_group_label>Orthopedic: PONV Prophylaxis Aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Totally intravenous Anesthesia (TIVA)</intervention_name>
    <description>This randomized group will receive propofol (TIVA) intravenously with titration to desired amnestic and anesthetic goals.</description>
    <arm_group_label>Major Abdominal: Primary Anesthetic TIVA</arm_group_label>
    <arm_group_label>Orthopedic: Primary Anesthetic TIVA (Propofol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stroke volume comparator</intervention_name>
    <description>For this randomized group, fluids will be replaced by keeping stroke volume and cardiac output within appropriate limits to optimize blood pressure and heart rate.</description>
    <arm_group_label>Major Abdominal: Fluid Therapy Stroke Volume Optimization</arm_group_label>
    <arm_group_label>Orthopedic: Fluid Therapy Stroke Volume Optimization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid Therapy</intervention_name>
    <description>This randomized Maintain euvolemia by measuring fluid output and calculate losses by surgical type. Replace fluid as appropriate with crystalloid, while maintain blood pressure and heart rate.</description>
    <arm_group_label>Major Abdominal: Fluid Therapy Maintain Euvolemia</arm_group_label>
    <arm_group_label>Orthopedic: Fluid Therapy Maintain Euvolemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>This randomized group will receive ketamine intravenously during the surgery.</description>
    <arm_group_label>Major Abdominal: Analgesia Adjuncts Ketamine</arm_group_label>
    <arm_group_label>Major Abdominal: Anesthesia Adjuncts Ketamine and Lidocaine</arm_group_label>
    <arm_group_label>Orthopedic: Analgesia Adjuncts Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>This randomized group will receive lidocaine intravenously during and after the surgery.</description>
    <arm_group_label>Major Abdominal: Anesthesia Adjuncts Ketamine and Lidocaine</arm_group_label>
    <arm_group_label>Major Abdominal: Anesthesia Adjuncts Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraoperative opioids</intervention_name>
    <description>This randomized group will receive intraoperative intravenous opioid infusions.</description>
    <arm_group_label>Major Abdominal: Intraoperative Opioid</arm_group_label>
    <arm_group_label>Orthopedic: Intraoperative Opioid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primary Anesthetic Spinal</intervention_name>
    <description>This randomized group will receive spinal anesthesia and sedation as needed intravenously with titration to desired amnestic and anesthetic goals</description>
    <arm_group_label>Orthopedic: Primary Anesthetic Spinal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primary Anesthetic Volatile Agent</intervention_name>
    <description>This randomized group will receive inhalational volatile anesthetic (ie sevoflurane) titration to desired amnestic and anesthetic goals.</description>
    <arm_group_label>Major Abdominal: Primary Anesthetic Volatile Agent</arm_group_label>
    <arm_group_label>Orthopedic: Primary Anesthetic Volatile Agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Postoperative Gabapentin</intervention_name>
    <description>This randomized group will receive gabapentin depending on age of each patient. If patients age &lt;65, receive 1 dose of 300mg gabapentin. If patients age ≥ 65 receive 1 dose of 100mg.</description>
    <arm_group_label>Major Abdominal: Postoperative Oral Analgesia Adjunct</arm_group_label>
    <arm_group_label>Orthopedic: Postoperative Oral Analgesia Adjunct</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Patient is seen in preoperative appointment prior to surgery, and&#xD;
&#xD;
          2. Patient has been scheduled for a surgical type in which ERP has been implemented.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Seymour, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Neal, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Holder-Murray, MD, FACS</last_name>
    <phone>877-684-7189</phone>
    <email>holdermurrayjm@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Esper, MD, MBA</last_name>
    <phone>412.647.6644</phone>
    <email>espersa@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hesper Wong, MD</last_name>
      <phone>415-595-9936</phone>
      <email>wonghp@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hesper Wong, BS</last_name>
      <phone>415-595-9936</phone>
      <email>wonghp@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hesper Wong, BS</last_name>
      <phone>415-595-9936</phone>
      <email>wonghp@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Passavant</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hesper Wong, BS</last_name>
      <phone>415-595-9936</phone>
      <email>wonghp@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jennifer Holder-Murray</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>perioperative</keyword>
  <keyword>enhanced recovery</keyword>
  <keyword>patient-directed care</keyword>
  <keyword>randomized embedded multifactorial adaptive platform</keyword>
  <keyword>REMAP</keyword>
  <keyword>ERP</keyword>
  <keyword>90-day hospital free days</keyword>
  <keyword>length of stay</keyword>
  <keyword>perioperative optimization</keyword>
  <keyword>oral morphine equivalents</keyword>
  <keyword>postoperative nausea and vomiting</keyword>
  <keyword>readmission</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Perphenazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant-level data underlying the results reported in journal articles, subject to appropriate security controls, may be available for sharing with other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Relevant data may be available 1 year following publication.</ipd_time_frame>
    <ipd_access_criteria>Data access is subject to a methodically sound proposal and the necessary data sharing agreements.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

